Table 3. Changes in T-TAS® Parameters, PT-INR and APTT at Trough and Peak in Blood in the Rivaroxaban and Apixaban Groups.
Rivaroxaban (n = 6) |
Apixaban (n = 10) |
|||
---|---|---|---|---|
Trough | Peak | Trough | Peak | |
AR-T10 (min) | 9.2 ± 2.9 | 12.3 ± 2.3 | 11.9 ± 2.5 | 15.5 ± 3.2* |
AR-T80 (min) | 13.7 ± 3.2 | 18.3 ± 3.5* | 18.3 ± 3.1† | 22.0 ± 3.3* |
PL-T10(min) | 2.4 ± 0.7 | 2.4 ± 1.5 | 2.9 ± 1.3 | 3.5 ± 1.0 |
PL-T60 (min) | 6.7 ± 1.3 | 6.2 ± 0.8 | 8.3 ± 0.8 | 8.0 ± 0.3 |
PT-INR | 1.2 ± 0.2 | 1.3 ± 0.2 | 1.1 ± 0.1 | 1.2 ± 0.1 |
APTT (s) | 34.4 ± 5.3 | 40.7 ± 14.3 | 31.4 ± 2.3 | 31.9 ± 2.8 |
Continuous variables are expressed as mean ± SD. *P < 0.05 vs. trough, †P < 0.05 vs. rivaroxaban group.